Predictors of disease severity, clinical course, and therapeutic outcome in COVID-19 patients: our experience with 1,700 patients

Z. ERGENC[1], H. ERGENC[1], S. ARAÇ[2], İ.H. TÖR[3], M. USANMAZ[4], E. ALKILINÇ[5], C. KARACAER[6], T. KAYA[6], A. NALBANT[6], S. GÖRGÜN[7], A. ÖZTÜRK[8], I. YILDIRIM[9]

[1]Department of Internal Medicine, Ayancık Government Hospital, Sinop, Turkey
[2]Department of Emergency Medicine, University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey
[3]Department of Anesthesiology and Reanimation, University of Health Sciences, Erzurum, Turkey
[4]Department of Infectious Diseases and Clinical Microbiology, Gazi Government Hospital, Samsun, Turkey
[5]Department of Pulmonology, Atatürk State Hospital, Sinop, Turkey
[6]Department of Internal Medicine, Sakarya University Training and Research Hospital, Sakarya, Turkey
[7]Department of Microbiology and Clinical Microbiology, Samsun Univercity Training and Research Hospital, Samsun, Turkey
[8]Department of Emergency Medicine, Çorum Erol Olçok Training and Research Hospital, Çorum, Turkey
[9]Department of Internal Medicine, Görele Government Hospital, Giresun, Turkey

Abstract. – **OBJECTIVE:** Our study aimed at investigating the impacts of demographic, hematological, and biochemical factors on the clinical course and the prognostic outcome in adult COVID-19 patients.

PATIENTS AND METHODS: This retrospective study was performed in the internal medicine departments of two hospitals, and data were extracted from the medical files of 1,700 adult COVID-19 patients (836 females, 49.2%; 864 males, 50.8%) with an average age of 48.23 ± 16.68 (range: 18-93). Clinical data included baseline descriptives, prior medical history, admission date, treatment, and hematological and biochemical blood test results. The relationship between the survival, length of hospitalization, hematological, and biochemical parameters was investigated.

RESULTS: Advanced age ($p<0.001$), presence of at least on comorbid disease ($p=0.045$), increased length of hospitalization ($p=0.006$), elevated white blood cell ($p=0.001$) and neutrophil ($p=0.002$) counts, increased serum levels of glucose ($p=0.027$), blood urea nitrogen ($p<0.001$), AST ($p=0.006$), LDH ($p<0.001$), CRP ($p>0.001$), and D-dimer ($p=0.001$). In contrast, diminution of serum levels of albumin ($p<0.001$), ALT ($p=0.028$), calcium ($p=0.022$), and platelet count ($p=0.010$) were associated with increased mortality. There was a positive and weak relationship between serum D-dimer levels and length of hospitalization.

CONCLUSIONS: Our data imply that identifying and validating indicators that predict COVID-19 disease progression to improve health outcomes is crucial. Age, comorbidities, immunological response, radiographic abnormalities, laboratory markers, and signs of organ dysfunction may all predict poor outcomes individually or collectively. Identifying characteristics that predict COVID-19 problems is critical to guiding clinical management, improving patient outcomes, and allocating limited resources.

Key Words:
COVID-19, Severity, Prognosis, Outcome.

Introduction

COVID-19, a coronavirus infection caused by SARS-CoV-2, has strained healthcare systems. The infection spreads quickly, and the lack of universal testing and personal protective equipment has aggravated the situation, as has the prevalence of silent infections. Because of the vast number of COVID-19-infected individuals who present to various hospitals, a thorough understanding of the clinical, radiographic, and laboratory findings connected to higher severity of disease severity and death is required. Identifying

potential risk factors for illness progression could be immensely valuable for healthcare personnel in triaging patients, customizing treatment, monitoring clinical progress, and allocating sufficient support at all levels to prevent disease progress and death[1,2].

The SARS-CoV-2 characteristic of primary dormancy signs is another element leading to the fast prevalence and dangerously large number of affected patients. Fever with a quick start, coughing, and dyspnea are the most prevalent symptoms of COVID-19. Complications include pneumonia, renal failure, bacterial superinfections, coagulation problems, and thrombosis. Several clinical and demographic variables, such as advanced age, cardiovascular disease, and diabetes, are associated with poor outcomes and higher risks of mortality. In more vulnerable patients, such as infants, children, the elderly, and pregnant women, this knowledge gap has an impact on infection risk, illness progression, and outcomes. It is critical to understand better the risks of these vulnerable patients to improve and personalize their treatment and prevention techniques[2,3].

Regarding the extent of precautions and limits adopted by countries, COVID-19 mortality and morbidity rates differ substantially. The epidemiology of COVID-19 is substantially variable due to socio-cultural or lifestyle disparities among residents, as well as disparities in-country health policy. As a result, the fundamental causes of the severe pandemic outbreak need to be elucidated, and we aimed to investigate the impacts of demographic, hematological, and biochemical factors on the clinical course and the prognostic outcome in adult COVID-19 patients.

Patients and Methods

Study Design

Between 01.04.2021 and 01.08.2021, this retrospective cohort was conducted in the internal medicine departments of two institutions. Before the trial, the local institutional review board approved (GOKA/2021/8/9). Patients or their immediate family signed a written informed consent form. Data were gathered from the hospital databases, including the medical records of 1,700 adult patients. Our series consisted of 1,700 COVID-19 patients (836 females, 49.2%; 864 males, 50.8%) with an average age of 48.23 ± 16.68 (range: 18-93). Clinical data were gathered directly from the institutional computerized patient database, including baseline descriptives, prior medical records, admission date, treatment process, and biochemical and hematological test results.

Patients under 18 with comorbidities that could compromise immune functions, such as recent chemotherapy, hematological malignancies, and autoimmune illness, were excluded from the study.

Diagnostic Study

Nasal and pharyngeal swabs were analyzed for COVID-19 infection *via* quantitative real-time reverse transcriptase-polymerase chain reaction (qPCR). COVID-19 was diagnosed and treated based on the World Health Organization (WHO) interim standards and the Turkish Ministry of Health's COVID-19 Diagnosis and Treatment Program[4-6]. The study population was divided into three groups, based on the Turkish Ministry of Health's COVID-19 guide: (1) hospitalized patients with severe clinical conditions, such as oxygen saturation below 90% breathing room air, bilateral diffuse pulmonary infiltrates, and tachypnoea (30/min); (2) out-patient follow-up of participants with a mild clinical condition; (3) cases were classified as critical when patients met one of the following criteria: a. respiratory failure and the need for mechanical ventilation, b. shock, c. custodial care in the ICU because of organ failure other than lung failure[7].

Patients underwent routine blood testing, chemical and immunological investigations, and chest CT scanning to establish the COVID-19 severity. A serial chest CT scan was conducted every other day to track illness progression and therapy success.

Chest computed tomography (CT) scans were accomplished using a particular inspiratory period in a commercial multi-detector CT scanner (Optima CT540, GE Healthcare, USA). Patients were told to hold their breath to reduce artifacts and motion. The following settings were used to create computed tomography images: tube voltage of 100-120 kVp; effective tube current of 110-250 mAs; detector collimation of 0.625 mm; slice thickness of 1 mm; slice interval of 1 mm.

In our hospital's laboratory, blood samples were tested using normal methods. A standard approach was used to evaluate blood samples. Vacuum tubes were used to collect venous blood samples for hematological and biochemical analysis. The sample was centrifuged for 10 minutes at 3,000 RPM after the blood had coagulated.

The tubes containing K3-EDTA were utilized to investigate the complete blood count (CBC). An automated hematological analyzer was used to determine the quantity of CBC parameters (XT2000i, Sysmex, Osaka, Japan). Biochemical and hematological tests were performed on a 15 mL peripheral blood sample. After centrifugation at 3,000 rpm, serum was extracted and kept at -20°C until analysis. The VITROS 5600 Integrated Immunodiagnostic System was used to examine serum biochemistry (VITROS 5600, Johnson, NJ, USA).

Statistical Analysis

The IBM Statistical Package for Social Sciences (SPSS) Statistics v. 21 software (IBM Corp., Armonk, NY, USA) and the easyROC web tool[8] were used to analyze our data. The mean and standard deviation of descriptive data, as well as the median and minimum-maximum values, were used. Numbers and percentages are used to represent categorical variables. The Kolmogorov-Smirnov test was used to test the assumption of normality. The Mann-Whitney U test was used to compare two independent groups. Spearman's correlation coefficients were used to analyze the link between quantitative variables. The univariate logistic regression test was used to estimate the factors influencing survival. Finally, the area under the ROC curve was used to evaluate the performance of clinical factors in assessing survival. Statistical significance was defined as a *p*-value lower than 0.05.

Outcome Parameters

Data for the baseline descriptives (such as age and sex), prognostic outcome, comorbidities, medical history, chest computed tomography findings, length of hospitalization, duration of intensive care unit stay, and disease severity were extracted from the hospital records. The complete blood count and serum biochemistry studies included the measurements of mean platelet volume, white blood cell count, platelet count, red cell distribution width, as well as serum levels of glucose, calcium, potassium, sodium, blood urea nitrogen, albumin, alanine aminotransferase (ALT), creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), D-dimer, ferritin, and C-reactive protein (CRP). The impacts of these variables on the therapeutic outcome in COVID-19 patients were sought.

Results

Our series consisted of 1,700 patients (836 females, 49.2%; 864 males, 50.8%) with an average age of 48.23 ± 16.68 (range: 18-93). A total of 479 patients (28.4%) had comorbidities. As for the prognostic outcome, mortality was reported in 32 patients (2.0%), and the length of hospitalization was 5.03 ± 3.60 days (range: 0-32 days) (Table I).

As shown in Table II, the impacts analysis of demographic and clinical variables on survival yielded that advanced age ($p<0.001$), presence of at least 1 comorbid disease ($p=0.045$), increased length of hospitalization ($p=0.006$), elevated white blood cell ($p=0.001$) and neutrophil ($p=0.002$) counts, increased serum levels of glucose ($p=0.027$), blood urea nitrogen ($p<0.001$), AST ($p=0.006$), LDH ($p<0.001$), CRP ($p>0.001$), and D-dimer ($p=0.001$). In contrast, diminution of serum levels of albumin ($p<0.001$), ALT ($p=0.028$), calcium ($p=0.022$), and platelet count ($p=0.010$) were associated with increased mortality (Table II).

Table III demonstrates the relationship between clinical variables and length of hospitalization. We noted a positive and weak relationship between serum D-dimer levels and length of hospitalization (r=0.322, $p<0.001$; Table III).

Table I. The demographic and clinical features of our population (n=1700).

Variable		Statistics
Age (mean ± std. deviation)		48.23 ± 16.68 (range: 18-93)
Sex	Female	836 (49.2%)
	Male	864 (50.8%)
Comorbidity	No	1,208 (71.6%)
	Yes	479 (28.4%)
Survival	Alive	1,570 (98.0%)
	Dead	32 (2.0%)
Length of hospitalization (mean ± std. deviation)		5.03 ± 3.60 (range: 0-32)

Table II. The analysis of the impacts of demographic and clinical measurements on survival.

	Survival			
	Alive **(n = 1570)**	**Dead** **(n = 32)**	**Odds Ratio** **(95% CI)**	***p*-value**
Age (years)	47.38±16.45	74.5 ± 10.50	1.145 (1.105-1.186)	**< 0.001***
Sex (Female)	808 (51.5)	16 (50.0)	1.060 (0.527-2.135)	0.870
Comorbidity	0 [0-25]	2 [0-9]	1.090 (1.002-1.186)	**0.045***
Length of hospitalization (days)	4 [0-32]	4.5 [1-23]	1.103 (1.029-1.182)	**0.006***
White blood cell count (cells/mL)	5.89 [0.89-76.2]	8.5 [3.9-66.34]	1.123a (1.035-1.218)	**0.001***
Neutrophil count (cells/mL)	3.8 [0.0-69.9]	6.5 [3.4-63.6]	1.147a (1.051-1.253)	**0.002***
Lymphocyte count (cells/mL)	1.42 [0.11-136]	0.78 [0.2-5.77]	0.656a (0.312-1.379)	0.266
Platelet count (cells/µL)	207 [11-738]	204 [96-628]	1.005a (1.001-1.009)	**0.010***
RDW (%)	13.3 [10.6-111.8]	14.45 [12.4-23.1]	1.035a (0.978-1.095)	0.235
MPV (fL)	10.1 [7-17]	10.2 [8.4-16.4]	1.272a (0.946-1.710)	0.112
Glucose (mg/dL)	106 [48-476]	133 [70-532]	1.005a (1.001-1.010)	**0.027***
Blood urea nitrogen (mg/dL)	27 [1-178]	58.35 [23-267]	1.039a (1.025-1.053)	**< 0.001***
Creatinine (mg/dL)	0.8 [0.08-99]	1.3 [0.69-10.21]	1.028a (0.974-1.084)	0.318
Sodium (mEq/L)	138 [66-4,137]	136 [129-328]	1.00a (0.998-1.002)	0.988
Potassium (mEq/L)	4 [3-43,894]	4.35 [3-136]	1.000a (0.999-1.001)	0.845
Calcium (mg/dL)	9 [0-12.2]	8.35 [4.2-9.1]	0.665a (0.469-0.943)	**0.022***
Albumin (g/dL)	40 [0-47,160]	37.5 [7-45]	0.856a (0.803-0.913)	**< 0.001***
AST (U/L)	23 [5-669]	32.5 [10-199]	1.009a (1.003-1.015)	**0.006***
ALT (U/L)	21 [6-228]	17.5 [8-187]	1.017a (1.002-1.032)	**0.028***
LDH (U/L)	233 [0-2,005]	322.5 [150-1,317]	1.004a (1.002-1.006)	**< 0.001***
CRP (mg/L)	12.9 [0-350]	110.55 [2-350]	1.015a (1.009-1.021)	**< 0.001***
D-dimer (ng/mL)	170.5 [0-36,480]	905.5 [121-36,000]	1.000a (1.0-1.0)	**0.001***
Ferritin (µg/L)	150 [1.2-3,154]	305 [18.8-2,000]	1.001a (1.001-1.002)	0.065

aSince age, comorbidity, and length of hospitalization have significant impacts on survival, a correction has been performed to eliminate the effects of these 3 variables on the other parameters during the analysis. *Statistically significant; CI: confidence interval; RDW: red cell distribution width; MPV: mean platelet volume; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; CRP: C-reactive protein.

The performances of clinical variables for the estimation of prognostic outcomes are shown in Table IV. Accordingly, the variables with the highest potential to estimate survival were creatinine (93.7%), D-dimer (88.9%), blood urea nitrogen (87.2%), and neutrophil count (80.9%), and LDH (75.9%), respectively. Lower levels of albumin, calcium, salt, and lymphocyte count in the blood were all linked to an increased risk of death (Table IV).

Discussion

The current study investigated whether clinical, hematological, and biochemical variables significantly impacted the clinical course, therapeutic outcomes, and prognosis in adult COVID-19 patients. Our data yielded that advanced age, presence of at least one comorbid disease, increased length of hospitalization, elevated white blood cell and neutrophil counts, increased serum levels of glucose, blood urea nitrogen, AST, LDH, CRP, and D-dimer were associated with increased mortality. On the other hand, decreased serum levels of albumin, ALT, calcium, and platelet count were associated with higher mortality. Remarkably, there was a positive and weak relationship between serum D-dimer levels and length of hospitalization in adult COVID-19 patients.

Some COVID-19 patients did not develop hypoxemia or respiratory stress, suggesting that SARS-CoV-2 infection is a heterogeneous illness. One accurate and practical biomarker is required to prognosticate the COVID-19 pneumonia severity[9]. The BCG vaccination does not affect the COVID-19 pneumonia severity. Low income and age are the primary causes of COVID-19 pneumonia severe[10].

Mousavi et al[11] looked at the demographics, outcome, hematology-related, and laboratory parameters of COVID-19 patients admitted to a tertiary care hospital. They tried to figure out what hematologic factors were linked to death in the 24% of our patients who died during their stay. In prior investigations, it was discovered that being male and older increased the risk of in-hospital mortality[12-14].

Table III. The relationship between clinical variables and length of hospitalization.

Variable	Length of hospitalization (n = 1700)	
	r[a]	p-value
White blood cell count (cells/mL)	-0.068	0.005*
Neutrophil count (cells/mL)	0.004	0.872
Lymphocyte count (cells/mL)	-0.193	< 0.001*
Platelet count (cells/μL)	-0.155	< 0.001*
Red cell distribution width (%)	0.089	< 0.001*
Mean platelet volume (fL)	0.024	0.327
Glucose (mg/dL)	0.133	< 0.001*
Blood urea nitrogen (mg/dL)	0.059	0.014*
Creatinine (mg/dL)	0.043	0.078
Sodium (mEq/L)	-0.215	< 0.001*
Potassium (mEq/L)	0.024	0.333
Calcium (mg/dL)	-0.261	< 0.001*
Albumin (g/dL)	-0.031	0.203
AST (U/L)	0.127	< 0.001*
ALT (U/L)	-0.025	0.311
LDH (U/L)	0.143	< 0.001*
CRP (mg/L)	0.234	< 0.001*
D-dimer (ng/mL)	0.322	< 0.001*
Ferritin (μg/L)	0.103	< 0.001*

[a]Spearman correlation coefficient. Both *p* and *r* values must be considered during analysis of the relationship between a variable and the correlation coefficients must be interpreted as follows: 0.0-0.30: negligible; 0.31-0.50: low; 0.51-0.70: moderate; 0.71-0.90: high; 0.91-1.00: very high.

The average age of their hospitalized patients was 60 years old, with non-survivors nearly ten years older than survivors. Around 67% of non-survivors were over 60 years old. The deceased were primarily male and elderly, according to Yang et al[15]. Even though male patients were more likely to die, sex did not have a significant impact on mortality[11]. An immune response

Table IV. The performances of clinical variables for the estimation of survival.

Variable	AUC	95% CI	Cut-off value	Sensitivity	Specificity
White blood cell count	0.725	0.63-0.82	9.65	0.469	0.874
Neutrophil count	0.809	0.744-0.874	5.3	0.719	0.745
Lymphocyte count*	0.743	0.640-0.847	0.8	0.562	0.897
RDW	0.719	0.634-0.805	13.8	0.688	0.691
Glucose	0.613	0.498-0.727	129	0.562	0.765
Blood urea nitrogen	0.872	0.812-0.933	50.1	0.656	0.936
Creatinine	0.937	0.760-0.913	1	0.781	0.807
Sodium*	0.659	0.540-0.778	136	0.625	0.730
Potassium	0.685	0.561-0.809	4.1	0.656	0.823
Calcium*	0.695	0.613-0.777	8.9	0.75	0.669
Albumin*	0.699	0.602-0.796	32	0.375	0.950
AST	0.692	0.593-0.791	28	0.719	0.642
LDH	0.759	0.671-0.846	252	0.844	0.587
CRP	0.854	0.784-0.923	52	0.844	0.800
D-dimer	0.889	0.834 -0.944	342	0.929	0.785

*Lower values indicate a higher risk for mortality. The table presents only the variables that yield significant results as for the values in the area under the ROC curve. For each variable, the optimal cut-off values with the highest predictive potential for the estimation of prognostic outcome as well as their sensitivities and specificities have been presented. For e.g. The potential of neutrophil count for estimation of the prognostic outcome is 80.9%. The opitmal cut-off point is 5.3 and the sensitivity and specificity at this point is 0.719 and 0.745, respectively. AUC: area under curve; CI: confidence interval; RDW: red cell distribution width; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CRP: C-reactive protein.

irregularity and a lack of adaptive immunity are the causes of severe inflammatory responses in patients with COVID-19[16]. Thrombocytopenia and decreased nadir platelet counts have been recorded in non-survivors[17].

Serum CRP levels were considerably greater in non-survivors compared to discharged COVID-19 patients, according to Ruan et al[17]. According to Pan et al[18], increased CRP values were a common laboratory abnormality in individuals with COVID-19. Levi et al[19] discovered a raised D-dimer concentration and increased prothrombin time in COVID-19 patients as typical signs of coagulopathy. Other laboratory irregularities in COVID-19 that might be linked to thrombotic microangiopathy and coagulopathy include ferritin concentrations and high LDH[20].

In COVID-19, Yuan et al[21] found that a decrease in serum LDH could indicate a good response to treatment. A minor increase in white blood cell count was seen in patients with acute illness, but a clinically significant increase was seen in individuals who died. As a result, a considerable rise in WBCs in patients with severe disease could indicate clinical deterioration and a higher risk of poor outcomes. Although an increase in neutrophils may cause WBCs to increase, lymphocytes, monocytes, and eosinophils may decrease. Lymphocytes are thought to be essential for eliminating virally infected cells in the SARS virus[22], and survival may be related to the capacity to revive lymphocytes destroyed by the virus[23].

Both substantial and catastrophic outcomes are possible. Patients with a positive test of COVID-19 had significant cardiac and muscle injury biomarkers. Non-survived patients showed a considerable level of high cardiac troponin at the time of admission, indicating a risk of cardiac injury caused by multiple organ failure progression, viral myocarditis, and secondary cardiac caused by organ-targeted diseases. A significant increase in liver enzymes (ALT and AST) and renal indicators (blood urea nitrogen) reveals a picture of multiple organ failure[24].

Plasma CRP levels were associated with the COVID-19 pneumonia severity. As a result, it could help distinguish between patients with mild COVID-19 pneumonia and those with moderate to severe COVID-19 pneumonia. These findings could help clinicians better stratify patients for transfer to an intensive care unit by serving as an early warning sign of severe disease[25].

The clinical sequence of patients with severe COVID-19 from admission to discharge was reported in this study, with various outcomes. Lymphocyte, CRP, and LDH dynamic monitoring could help predict the severe patients' prognosis. Furthermore, the fatal aspect of COVID-19 was primarily related to significant systemic inflammation that caused cardiac failure[26]. Comorbidities, age, secondary infection, and higher indicators in inflammation were predictors of a fatal result in COVID-19 cases. COVID-19 death could be related to virus-activated "cytokine storm syndrome" or fulminant myocarditis, according to the findings[17].

Limitations

It is essential to note the limitations of our study. Our findings may be influenced by the retrospective design and possibly socioeconomic factors. Given the pandemic's rapid spread, these findings are clinically significant and may help clinicians in identifying and treating persons with a higher risk of acquiring the severe disease. Therefore, our results should be regarded as preliminary and exploratory. Because participants who are more likely to die exhibit significant variations in some of these co-variates, the correlations we observe should not be assumed to represent cause and effect.

Conclusions

Our data imply that identifying and validating indicators for predicting COVID-19 disease progress to improve health outcomes is crucial. Age, immunological response, comorbidities, radiographic abnormalities, signs of organ dysfunction, and laboratory markers could predict poor outcomes individually or collectively. Because SARS-CoV-2 has a tropism for various tissues, such as the brain, endothelium, heart, kidney, liver, and respiratory system, predicting the COVID-19 severity is much more challenging. Identifying characteristics that predict COVID-19 problems is critical to guiding clinical management, improving patient outcomes, and allocating limited resources.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Ethics Approval

This study was conducted in accordance with the ethical rules with the approval of Health Sciences University Samsun Training and Research Hospital ethics committee (decision no 2021/8/9, 21.04.2021).

ORCID ID

Hasan Ergenc: 0000-0003-0519-0264; Zeynep Ergenc: 0000-0001-7598-4508; Songül Araç: 0000-0001-6830-3639; İbrahim Hakkı Tör: 0000-0003-0246-3220; Mustafa Usanmaz: 0000-0002-5369-2560; Ersin Alkılınç: 0000-0002-6456-6623; Cengiz Karacaer: 0000-0002-7164-4810 Tezcan Kaya: 0000-0003-0483-2333; Ahmet Nalbant: 0000-0003-4756-3575; Selim Görgün: 0000-0001-5841-591X; Ahmet Öztürk: 0000-0002-9678-2195; Ilhan Yıldırım: 0000-0003-0600-7249.

References

1) Gallo Marin B, Aghagoli G, Lavine K. Predictors of COVID-19 severity: A literature review. Rev Med Virol 2021; 31: 1-10.

2) Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513.

3) Jutzeler CR, Bourguignon L, Weis CV. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 37: 101-125.

4) WHO. COVID-19 Clinical management. Living guidance. 25 January 2021. Accessed 5 May 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.

5) Yuce M, Filiztekin E, Ozkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron 2021; 172: 112-152.

6) Simsek Yavuz S, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50: 611-619.

7) COVID-19 guide. Available at: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf.

8) Goksuluk D, Korkmaz S, Zararsiz G, Karaagaoglu AE. EasyROC: an interactive web-tool for ROC curve analysis using R language environment. R Journal 2016; 8: 213-230.

9) Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020; 19: 18-28.

10) Aksu K, Naziroğlu T, Özkan P. Factors determining COVID-19 pneumonia severity in a country with routine BCG vaccination. Clin Exp Immunol 2020; 202: 220-225.

11) Mousavi SA, Rad S, Rostami T. Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. Hematology 2020; 25: 383-388.

12) Wu C, Chen X, Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934-943.

13) Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062.

14) Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475-481.

15) Yang X, Yang Q, Wang Y. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 2020; 18: 1469-1472.

16) Xiang N, Havers F, Chen T. Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis 2013; 19: 1784-1784.

17) Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846-859.

18) Pan F, Ye T, Sun P. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020; 296: 55-64.

19) Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7: 438-440.

20) Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062.

21) Yuan J, Zou R, Zeng L. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res 2020; 69: 599-606.

22) He Z, Zhao C, Dong Q. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis 2005; 9: 323-330.

23) Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med 2020; 8: 24-29.

24) Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58: 1021-1028.

25) Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020; 19: 18-29.

26) Pan F, Yang L, Li Y. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci 2020; 17: 1281-1292.